Skip to main content Accessibility help

Assessing metabolic syndrome in people with ID (intellectual disabilities) on antipsychotic medication

  • A. Carballedo (a1) (a2), A. Doran (a1), M. Doyle (a2), S. Flavin (a1), J. Tyrrel (a1), F. Kelly (a1), S. Guerin (a1) and P. Dodd (a1)...



To identify whether clinical information routinely collected and recorded on clinical files is available for the identification of metabolic syndrome and to assess the prevalence of risk factors for the syndrome in a sample of people with intellectual disabilities (ID) and mental illness treated with antipsychotic medication.


A retrospective analysis was performed for 76 adults with ID and comorbid mental illness, for whom treatment with antipsychotic medication was established. Statistical analysis was performed using SPSS 16.0. The Student t-test for parametric data and χ2-test for non-parametrical data were used.


Five of the six criteria for metabolic syndrome were available in all or a high proportion of the files, however no measurement for waist circumference was recorded in any of the files. Aripiprazole appears to be the least risky antipsychotic for metabolic syndrome.


It is important to develop a systematic protocol to record diagnostic variables for metabolic syndrome in at risk populations such as those with ID and mental illness treated with regular antipsychotics.


Corresponding author

*Address for correspondence: Dr A. Carballedo, LMC, MRCPsych, MD, Consultant Psychiatrist and Clinical Senior Lecturer, Institute of Neuroscience, Trinity College Dublin, College Green, Dublin D2, Ireland. (Email:;


Hide All
Alberti, KG, Zimmet, P, Shaw, J (2005). The metabolic syndrome – a new worldwide definition. Lancet 366, 10591062.
Alberti, KG, Zimmet, P, Shaw, J (2006). Metabolic syndrome – a new worldwide definition. A consensus Statement from the International Diabetes Federation. Diabetic Medicine 23, 469480.
American Psychiatric Association (2000). Diagnostic and Statistical Manual of Mental Disorders, DSM-IV, 4th edn. American Psychiatric Association: Arlington, VA, USA.
Anderson, PJ, Critchley, JA, Chan, JC, Cockram, CS, Lee, ZS, Thomas, GN, Tomlinson, B (2001). Factor analysis of the metabolic syndrome: obesity vs insulin resistance as the central abnormality. International Journal of Obesity and Related Metabolic Disorder 25, 17821788.
Angst, F, Stassen, HH, Clayton, PJ, Angst, J (2002). Mortality of patients with mood disorders: follow-up over 34–38 years. Journal of Affective Disorders 68, 167181.
Attux, C, Martini, LC, Elkis, H, Tamai, S, Freirias, A, et al. (2013). A 6-month randomized controlled trial to test the efficacy of a lifestyle intervention for weight gain management in schizophrenia. BMC Psychiatry 13, 60.
Bushe, CJ, Slooff, CJ, Haddad, PM, Karagianis, JL (2013). Weight change by baseline BMI from three-year observational data: findings from the Worldwide Schizophrenia Outpatient Health Outcomes Database. Journal of Psychopharmacology 27, 358365.
Cooper, SA, Smiley, E, Morrison, J, Allan, L, Williamson, A, Finlayson, J, Jackson, A, Mantry, D (2007). Psychosis and adults with intellectual disabilities. Prevalence, incidence, and related factors. Social Psychiatry and Psychiatric Epidemiology 42, 530536.
Correll, CU, Manu, P, Olshanskiy, V, Napolitano, B, Kane, JM, Malhotra, Ak (2009). Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. Journal of American Medical Association 302, 17651773.
Daumit, G, Goff, D, Meyer, J, Davis, V, Nasrallah, H, McEvoy, J, et al. (2008). Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophrenia Research 105, 175187.
De Hert, M, Hanssens, L, Van Winkel, R, Wampers, M, Van Eyck, D, Scheen, A, Peuskens, J (2007). A case series: evaluation of the metabolic safety of aripiprazole. Schizophrenia Bulletin 33 823830.
De Hert, M, Schreurs, V, Vancampfort, D, Van Winkel, R (2009). Metabolic syndrome in people with schizophrenia: a review. World Psychiatry 8, 1522.
De Hert, M, Vancampfort, D, Correl, CU, Mercken, V, Peuskens, J, Sweers, K, et al. (2011). Guidelines for screening and monitoring of cardiometabolic risk in schizophrenia: systematic evaluation. British Journal of Psychiatry 199, 99105.
De Winter, CF, Bastiaanse, LP, Hilgenkamp, TI, Evenhuis, HM, Echteld, MA (2011). Overweight and obesity in older people with intellectual disability. Research in Developmental Disabilities 33, 398405.
Gazizova, D, Puri, BK, Singh, I, Dhaliwal, R (2012). The overweight: obesity and plasma lipids in adults with intellectual disability and mental illness. Journal of Intellectual Disability Research 56, 895901.
Hilgenkamp, TI, Reis, D, van Wijck, R, Evenhuis, HM (2011). Physical activity levels in older adults with intellectual disabilities are extremely low. Research in Developmental Disabilities 33, 477483.
Hoang, U, Stewart, R, Goldacre, MJ (2011). Mortality after hospital discharge for people with schizophrenia and bipolar disorder: retrospective study of linked English hospital episode statistics, 1999–2006. British Medical Journal 343, d5422.
Holt, RIG, Abdelrahman, T, Hirsch, M, Dhesi, Z, George, T, Blincoe, T, et al. (2010). The prevalence of undiagnosed metabolic abnormalities in people with serious mental illness. Journal of Psychopharmacology 24, 867873.
International Diabetes Federation (IDF) (2006). The IDF consensus worldwide definition of metabolic syndrome, 2006. Communications Avenue Emile De Mot 19, B-1000 Brussels, Belgium.
Luo, B, Yang, Y, Nieman, D, Zhang, Y, Wang, J, Wang, R, Chen, P (2013). A 6-week diet and exercise intervention alters metabolic syndrome risk factors in obese Chinese children aged 11–13 years. Journal of Sport and Health Science 2, 236241.
Mackin, P, Bishop, D, Watkinson, H, Gallagher, P, Ferrier, IN (2007). Metabolic disease and cardiovascular risk in people treated with antipsychotics in the community. British Journal of Psychiatry 191, 2329.
McCreadie, RG (2003). Diet, smoking and cardiovascular risk in people with schizophrenia. Descriptive study. British Journal of Psychiatry 183, 534539.
McIntyre, RS, McCann, SM, Kennedy, SH (2001). Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities. Canadian Journal of Psychiatry 46, 273281.
McKee, JR, Bodfish, JW, Mahorney, SL, Heeth, WL, Ball, MP (2005). Metabolic effects associated with atypical antipsychotic treatment in the developmentally disabled. Journal of Clinical Psychiatry 66, 11611168.
Nesto, RW (2003). The relation of insulin resistance syndromes to risk of cardiovascular disease. Reviews in Cardiovascular Medicine 4, S11S18.
Royal College of Psychiatrists (2001). Diagnostic Criteria for Psychiatric Disorders for Use with Adults with Learning Disabilities. Royal College of Psychiatrists. London: Gaskell, 2001.
Rummel-Kluge, C, Komossa, K, Schwarz, S, Hunger, H, Schmid, F, Asenjo Lobos, C, Kissling, W, Davis, JM, Leucht, S (2010). Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophrenia Research 123, 225233.
Ryan, MC, Collins, P, Thakore, JH (2003). Impaired fasting glucose and elevation of cortisol in drug-naïve first-episode schizophrenia. American Journal of Psychiatry 160, 284289.
Sinnema, M, Maaskant, MA, van Schrojenstein Lantman-de Valk, HM, van Nieuwpoort, IC, et al. (2011). Physical health problems in adults with Prader–Willi syndrome. American Journal of Medical Genetics: Part A 155A, 21122124.
Sukanta, S, Chant, D, McGrath, J (2007). A systematic review of mortality in schizophrenia is the differential mortality gap worsening over time? Archives General Psychiatry 64, 11231131.
Tosch, G, Clifton, A, Bachner, M (2011). General physical health advice for people with serious mental illness. Cochrane Database of Systematic Reviews 2, CD008567.
Vinberg, M, Madsen, M, Breum, L, Kessing, LV, Fink-Jensen, A (2012). Metabolic syndrome in a cohort of affectively ill patients, a naturalistic study. Nordic Journal of Psychiatry 66, 142145.
Wallace, RA (2004). Risk factors for coronary artery disease among individuals with rare syndrome intellectual disabilities. Journal of Policy and Practice in Intellectual Disabilities 1, 4251.


Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed